openPR Logo
Press release

Hyperinsulinemia Therapeutics Pipeline Analysis 2018

06-04-2019 02:43 PM CET | Health & Medicine

Press release from: Pharma Proff

/ PR Agency: Hyperinsulinemia Therapeutics Pharma Proff

Hyperinsulinemia is a medical condition which is characterized by increased amount of insulin in blood. The primary cause of the disease is insulin resistance, which can also result in the development of type 2 diabetes.

Download the sample report at: https://www.pharmaproff.com/request-sample/1031

Insulinoma and nesidioblastosis are some other causes of hyperinsulinemia. Major symptoms of the disease are intense hunger, concentration difficulties, fatigue and obesity. People who have higher triglyceride and uric acid level, obesity, type 2 diabetes and hypertension are at a higher risk of developing hyperinsulinemia.

Get the detailed analysis at: https://www.pharmaproff.com/report/hyperinsulinemia-therapeutics-pipeline-analysis

Hanmi Pharmaceutical Co. Ltd. is currently developing HM15136, a long-acting glucagon analog, by using their LAPSCOVERY technology platform for the treatment of congenital hyperinsulinism. Moreover, Zealand Pharma A/S, and Heptares Therapeutics Ltd. are some other major companies involved in the development of therapeutic agents for the treatment of hyperinsulinemia.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1031

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperinsulinemia Therapeutics Pipeline Analysis 2018 here

News-ID: 1764303 • Views: 210

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Hyperinsulinemia

Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2 …
Researchmoz added latest report "Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. This report provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for type I diabetes, type
Major Progress| Diabetes and Associated Metabolic Conditions Drug Development Pi …
Researchmoz added Most up-to-date research on "Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018" to its huge collection of research reports. Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for type I diabetes, type II diabetes, hyperinsulinemia
Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2 …
This report provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for type I diabetes, type II diabetes, hyperinsulinemia and hyperglycemia, and features dormant and discontinued products. Diabetes refers to a group of metabolic diseases that result from defects in insulin secretion, insulin action or both of these. Type I diabetes
Hyperinsulinemia Market Segmentation Detailed Study With Forecast Up To 2017
Overview Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue and frequently hungry. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes and hypertension. Treatment includes Insulin secretion inhibiting agents, diet, exercise and other lifestyle changes.  Click here for
Hyperinsulinemia - Clinical Trials Rise Due to Higher Disease Incidences, H1 Rev …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free
Industry Future Trends Hyperinsulinemia Pipeline Review, H2 2016
"The Report Hyperinsulinemia - Pipeline Review, H2 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia Pipeline Review, H2 2016, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape. Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose.